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In a three-way crossover pilot study, the acute effects of tiotropium 18 mg inhalation on the
respiratory function and arterial blood gas tensions of 30 patients with stable chronic
obstructive pulmonary disease (COPD) were compared with those of salmeterol 50 mg and
formoterol 12 mg. In each study day, lung function and arterial blood gas analyses were
performed before and up to 180min after inhalation. All treatments significantly improved
lung function, increased DLco, decreased PaO2, and increased P(A-a)O2, with no change in
PaCO2. The effects of salmeterol and tiotropium on PaO2 were slower in onset and more
prolonged than those of formoterol but PaO2AUC0–180min was significantly greater for
formoterol and salmeterol than for tiotropium. It is likely that the significant but small
decreases in PaO2 and increases in P(A-a)O2 have been caused by pulmonary vasodilator
effects. Since the three agents were similar in inducing bronchodilation, we believe that
tiotropium is preferable in patients with hypoxemia caused by stable COPD because it
seems to carry a smaller risk of worsening systemic hypoxemia.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Both the Global Initiative for Obstructive Lung Disease
(GOLD) guidelines1 and American Thoracic Society (ATS)/
European Respiratory Society (ERS) position paper2 empha-Elsevier Ltd. All rights reserved.
2596621.
roma2.it (M. Cazzola).size the role of bronchodilators in symptomatic management
of all stages of chronic obstructive pulmonary disease
(COPD) and recommend, for moderate-to-very severe COPD,
use of regular treatment with long-acting bronchodilators,
including tiotropium, rather than short-acting bronchodila-
tors, with the choice depending on the availability of
medication and the patient’s response. The choice between
anticholinergic drugs and b-agonists as a first-line therapy
for patients with COPD is still a matter of debate. The choice
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Tiotropium is less likely to induce oxygen desaturation 1799of the specific agent depends on the availability of
medication and the patient’s response. However, Tashkin
and Cooper3 have emphasized the advantage of tiotropium,
a new long-acting anticholinergic bronchodilator, over long-
acting b2-agonists, although only few studies have compared
inhaled long-acting b-agonists and tiotropium in patients
with COPD and most of them have focused on the
improvement of spirometric data (usually as forced ex-
piratory volume in 1s [FEV1]).
4–12 Unfortunately, it is not
clear whether pulmonary function tests parallel sympto-
matic improvement and/or exercise performance because
studies that examined the effects of two classes of inhaled
bronchodilators on dyspnea and exercise ability are scant.
Another issue that has not been examined yet is the
possible difference in the impact of long-acting b2-agonists
and tiotropium on blood gases. It is known that the
administration of b-adrenergic agents to patients with
airways obstruction often results in a transient decrease in
partial pressure of oxygen in arterial blood (PaO2) despite
concomitant bronchodilation,13 whereas anticholinergic
bronchodilators have been shown to have relatively small
effects on arterial blood gases.14 This finding is potentially
important because it indicates that anticholinergic bronch-
odilators should be considered a safer choice. In fact, the
clinical relevance of changes in oxygenation may be
considerable for patients with COPD because findings
reflecting bronchodilation do not necessarily correlate with
the perception of breathlessness. Nevertheless, to date and
to our best knowledge no published study has compared the
effects of the three long-acting bronchodilators on the
arterial blood gas tensions of patients with stable COPD.
Patients and methods
Study population
Thirty outpatients with stable COPD were enrolled. Inclusion
criteria were: 445 years of age, current or former smoker
(410 pack-years), and a diagnosis of COPD as defined by the
ATS/ERS position paper.2 The diagnosis was substantiated by
spirometry. The presence of a postbronchodilator FEV1o80%
of the predicted value in combination with an FEV1/forced
vital capacity (FVC)o70% confirmed the presence of airflow
limitation that was not fully reversible. Exclusion criteria
included: unstable respiratory status within the previous 4
weeks, a known history of asthma or chronic respiratory
disease other than COPD, any clinically significant concur-
rent disease, a resting PaO2 of less than 55mmHg, or use of
long-term oxygen therapy, and a change in medication for
COPD within the 4 weeks prior to the screening visit. Each
patient gave informed consent and the study protocol was
approved by an independent ethics committee. Basal
characteristics of patients are illustrated in Table 1.
Study protocol
This was a three-way crossover pilot study. All patients
received tiotropium 18 mg, salmeterol 50 mg or formoterol
12 mg from dry powder inhalers (DPIs) under randomized,
crossover conditions. Each subject was studied for 3 days,
separated from one another by at least 4 days.On each study day, subjects were required to withhold
conventional inhaled bronchodilators for at least 12 h,
salmeterol and formoterol or long-acting theophyllines for
at least 24 h, and tiotropium for at least 48 h before study to
avoid or, at least, minimize any carryover effect of drugs.
Subjects receiving an inhaled corticosteroid were instructed
to take this as usual, together with all their usual
nonpulmonary medications. Short-acting inhaled b2-agonists
were permitted soon after each test when required.
Patients were asked not to consume cola drinks, coffee or
tea and not to smoke in the hours before and during the
investigation.
The study included: spirometry, body plethysmography,
diffusing capacity for carbon monoxide (DLco), and blood
gases. The blood gas analyzer output was checked daily with
a standard test sample. During the study period, the SD
values were 70.5mmHg for PaO2, 70.4mmHg for partial
pressure of carbon dioxide in arterial blood (PaCO2), and
70.008 for potential of hydrogen (pH). On each study day,
after a rest of 15min while the patient was breathing room
air, an arterial catheter was placed in the brachial artery.
Samples of arterial blood (5ml) were removed for measure-
ment of PaO2, PaCO2, and pH with a blood gas analyzer.
Then, each patient received one of the three study
treatments under supervision, with the order of treatment
being randomized. Blood gas analysis was repeated at 15,
30, 60, 120, and 180min, always in room air. All other tests
were performed at the same time intervals.
The changes in PaO2 and in FEV1 after each treatment,
from the baseline obtained on that day, were the
primary outcome variables. The magnitude of changes in
blood gas tensions and functional values at each analysis
time were compared among treatments. In addition, the
area between the PaO2 curve and the baseline value (area
under the curve [AUC]) was calculated with the trapezoidal
method. The paired t-test and analysis of variance (ANOVA)
were used to determine the significance of differences
among agents. Statistical significance was accepted at
po0.05.
We must highlight that the sample size of our study
was not calculated because this was a pilot investigation,
at least considering the impact of tiotropium and
formoterol on blood gases, but the confidence intervals
around the means that represent the plausible range in
which the true treatment effect may lie were always
reported.15Results
All patients completed the 3-day study. Their base-
line values of FEV1 and PaO2 were not significantly
(p40.05) different among the three treatments both as
absolute value and, for FEV1, also as percent of predicted
value.
As expected, all treatments significantly improved FEV1,
FVC, and inspiratory capacity (IC) and decreased specific
airway resistance (sRaw) at all time points when compared
to the baseline without major differences among the three
drugs (Fig. 1). Maximal changes from baseline were always
recorded at 120 or at 180min. FEV1 improved (%) by 14, 12,
and 17; FVC by 12, 12, and 13; IC by 21, 17, and 27; and
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Table 1 Demographic data and functional characteristics of patients.
Patient
(n)
Sex Age
(years)
Smoking
history
(pack/year)
Basal FEV1 (%
predicted)
Basal FVC (%
predicted)
Basal PaO2
(mmHg)
Basal
PaCO2
(mmHg)
Under regular
inhaled
corticosteroid
1 M 73 Ex-smoker 25 39 67.3 42.4 Yes
2 M 74 Ex-smoker 47 60 81.6 38.9 Yes
3 M 63 Ex-smoker 59 70 72.2 42.5 No
4 M 81 Ex-smoker 44 53 67.8 42.5 Yes
5 M 74 Ex-smoker 55 66 75.6 39.5 No
6 M 75 Ex-smoker 61 69 67.4 46.4 No
7 M 71 Ex-smoker 51 65 79.1 39.4 No
8 M 70 Ex-smoker 67 81 80.2 39.9 No
9 M 77 Ex-smoker 49 61 81.2 41.6 No
10 M 72 Ex-smoker 42 63 75.4 41.8 Yes
11 M 78 Ex-smoker 70 84 75.6 40.6 No
12 M 59 Smoker (100) 50 72 74.3 36.9 No
13 M 61 Ex-smoker 29 52 71.3 39.1 Yes
14 M 72 Ex-smoker 66 90 81.3 39.7 No
15 M 73 Ex-smoker 61 77 76.4 36.1 No
16 M 64 Ex-smoker 44 56 79.4 38.4 No
17 M 70 Ex-smoker 64 73 70.6 34.4 No
18 M 69 Ex-smoker 33 56 65.7 43.3 Yes
19 M 76 Ex-smoker 22 37 71.2 41.9 Yes
20 F 62 Ex-smoker 24 44 69.8 46.2 Yes
21 M 65 Ex-smoker 32 48 67.2 44.1 Yes
22 M 72 Ex-smoker 27 47 74.0 45.4 Yes
23 M 67 Smoker (50) 58 67 78.6 36.4 No
24 M 63 Ex-smoker 64 74 73.9 38.4 No
25 M 72 Smoker (50) 39 52 74.9 41.3 Yes
26 M 74 Smoker (40) 67 89 82.8 36.3 No
27 M 72 Ex-smoker 58 63 65.7 44.2 No
28 M 71 Ex-smoker 44 73 72.3 41.7 Yes
29 F 71 Ex-smoker 31 58 55.2 49.8 Yes
30 M 76 Ex-smoker 43 60 66.9 48.4 Yes
P. Santus et al.1800sRaw decreased (%) by 35, 30, and 32 after tiotropium,
salmeterol, and formoterol, respectively. Residual volume
(RV) decreased (%) by 16, 13, and 21, and thoracic gas
volume (TGV) by 12, 10, and 15, after tiotropium,
salmeterol, and formoterol, respectively (Fig. 2). All
treatments significantly improved (ml/min/mmHg) DLco by
1.6, 1.8, and 1.6 after tiotropium, salmeterol, and
formoterol, respectively (Fig. 2).
No significant changes were observed in PaCO2 after the
three different treatments (Fig. 3). However, PaO2 signifi-
cantly decreased (mmHg) by 1.7, 4.9, and 4.8 (Fig. 3), and
alveolar–arterial difference in oxygen tension [P(A-a)O2]
increased (mmHg) by 2.1, 5.0, and 4.5 (Fig. 3) after
tiotropium, salmeterol, and formoterol, respectively. The
effects of salmeterol and tiotropium on gas exchange
tended to be slower in onset and more prolonged than
those of formoterol, with a change that was sustained at
180min. Nevertheless, the PaO2AUC0–180min was greatest for
formoterol (3.59mmHg/h), next greatest for salmeterol
(2.83mmHg/h), and least for tiotropium (1.03mmHg/h)
and the differences among formoterol or salmeterol and
tiotropium with respect to AUC0–180min values were statis-
tically significant (Fig. 3).Discussion
The central finding of this pilot study was that all treatments
resulted in significant improvement in lung function and
significant but small decreases in PaO2 and increases in P(A-
a)O2, although the impact of tiotropium on PaO2 and P(A-a)O2
was smaller than that induced by salmeterol or formoterol. In
any case, the average decreases in PaO2 and increases in P(A-
a)O2 were quite small and of questionable clinical signifi-
cance. In fact, the average 5mmHg decrease in PaO2 from 75
to 70mmHg that we observed did not affect oxygen
saturation and hence was not clinically relevant.
Our data were in agreement with the results of the few
studies that have compared the impact of b2-agonists and
anticholinergic agents on blood gases.14,16–19 All of them, in
fact, reported that anticholinergic bronchodilators only
induce small and statistically insignificant effects on gas
exchange, whereas b-adrenergic agents result in a statisti-
cally significant decrease in the PaO2 despite concomitant
bronchodilation.20
The transient decrease in PaO2 with b-adrenergic agents
has been attributed to the pulmonary vasodilator action of
these agents21 due to the activation of b-adrenoceptors that
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Figure 1 Mean changes (7SE) in FEV1, FVC, IC, and sRaw with time after administration of formoterol (squares), salmeterol
(rhombi), and tiotropium (triangles). **po0.01 and ***po0.001 vs. baseline.
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Figure 2 Mean changes (7SE) in RV, TGV, and DLco with time after administration of formoterol (squares), salmeterol (rhombi), and
tiotropium (triangles). *po0.05, **po0.01 and ***po0.001 vs. baseline.
Tiotropium is less likely to induce oxygen desaturation 1801are present in pulmonary vessels,22 increasing blood flow to
poorly ventilated lung regions and thus increasing ventila-
tion–perfusion (VA/Q) inequality, a shunt-like effect, at
least in asthmatic patients.23,24 The anticholinergic agents
act more selectively in bronchial muscle receptors than in
myocardium and would be less likely to aggravate the VA/Q
disturbance.25 In effect, compared to adrenergic nerves, the
functional significance of cholinergic nerves26 and themuscarinic receptor subtype(s) involved27,28 in the regula-
tion of the tone of pulmonary circulation is less clear
although, at least in rats, muscarinic M3 receptor activation
is responsible for the pulmonary artery contraction induced
by acetylcholine.29
It is likely that the small improvement in DLco that we
have observed after the inhalation of the three long-acting
bronchodilators was related to the diminished pulmonary
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Figure 3 Mean changes (7SE) in PaO2, P(A-a)O2, PaO2AUC0–180min, and PaCO2 with time after administration of formoterol
(squares), salmeterol (rhombi), and tiotropium (triangles). *po0.05, **po0.01, and ***po0.001 vs. baseline, except for
PaO2AUC0–180min where
*po0.05 and **po0.01 vs. tiotropium.
P. Santus et al.1802vascular tone. However, it must be also mentioned that the
inter-session variability of DLco in healthy subjects and
those with pulmonary disease has been shown to be 5ml/
min/mmHg over 1 week.30 In any case, b2-agonists have
been suggested to induce a fall in pulmonary vascular
resistance also because of an increase in cardiac output31,32
and in right ventricular ejection,32,33 whereas there is no
documentation that this is the case for anticholinergic
agents.
We must highlight that in our study all patients but one
had PaO2 values greater than 60mmHg at baseline. This is an
important finding because it has been documented that b-
agonists cause an increase in VA/Q inequality in patients
having PaO2 values greater than 60mmHg which results in a
moderate fall in the PaO2, whereas in patients with PaO2
values less than 60mmHg, the highest mean sPAP and the
poorest spirometric performances demonstrate no signifi-
cant changes in VA/Q distributions or PaO2 after
b-agonists.34 It is clear, therefore, that our documentation
of drop in PaO2 after the inhalation of a long-acting
bronchodilator cannot be extended to patients with more
advanced disease.
In conclusion, in this study, all treatments resulted in
significant improvement in lung function and significant but
small decreases in PaO2 and increases in P(A-a)O2. The mild
deterioration of arterial blood gases after long-acting
bronchodilators shown in our study indicates a further VA/
Q worsening, but also that SaO2 should not change at all. In
any case, tiotropium might be preferable in patients with
hypoxemia caused by stable COPD because it seems to carry
a smaller risk of worsening systemic hypoxemia.Acknowledgment
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